Intrinsic Value of S&P & Nasdaq Contact Us

Genenta Science S.p.A. GNTA NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • IT • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Genenta Science S.p.A. (GNTA) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.

Analysts estimate Earnings Per Share (EPS) of $-0.48 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.49 vs est $-0.48 (missed -2.1%). Analyst accuracy: 98%.

GNTA Analyst Ratings

Buy
1
Ratings
1 Buy
Based on 1 analysts giving stock ratings to Genenta Science S.p.A. in the past 3 months
Rating breakdown
Buy
1 100%
100%
Buy
1 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

EPS Estimates — GNTA

98%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024 Actual –$0.49 vs Est –$0.48 ▼ 2.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — GNTA

Revenue Trend
Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message